Home Page

Katrin Karbstein, the co-leader of the Cancer Cell Biology Research Program in the Vanderbilt-Ingram Cancer Center, will now expand her focus to support her department’s mission across research, service, and education, with a special focus on faculty affairs. Read More

New study from Borden Lacy and Audrey Thomas represents a major step forward for vaccine development for C. diff, the leading cause of health care- and antibiotic-associated infection. Read More

A new study reveals mechanistic underpinnings of Crohn’s disease, including some vulnerabilities within the ascending colon. This work challenges the assumption that all regions of the gut respond similarly to inflammation, argues for region-specific treatments for the disease, and highlights a potential new target for treatment within the ascending colon. Read More

Shan Meltzer was named a Sloan Research Fellow, one of the most competitive honors available to young investigators, for her research into how the neural circuits responsible for touch and pain processing are built and organized. Read More

Ann Richmond outlines a promising therapeutic strategy that may re-sensitize treatment-resistant tumors to immunotherapy. The research introduces a three-drug combination that enhances immune activity and suppresses tumor-promoting immune cells. Read More

Dr. Teru Nakagawa, professor of molecular physiology and biophysics in the School of Medicine Basic Sciences, will deliver the inaugural Kairos Lecture on Thursday, Feb. 26, 2026. Read More

Whether they met at the bench or bonded over research setbacks, these alums prove that meaningful relationships can flourish alongside rigorous scientific training. In honor of Valentine’s Day, we asked them to share how they did it. Read More

The School of Medicine Basic Sciences is launching a new lecture series: “The Kairos Lectures: Research of Consequence at the Right Moment.” Read More

Vanderbilt trainees and postdocs explored Nashville’s biotech scene, starting with contract research organization Inotiv. Read More

In a new study published in Diabetes, researchers found that prolonged treatment with the GLP-1R agonist semaglutide led to changes in feeding habits and fuel use in an animal model, offering new insights into the behavioral and metabolic adaptations that accompany weight loss, weight maintenance, and rapid weight regain after stopping treatment. Read More